Acumen Pharmaceuticals Inc (ABOS) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s...

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...